Broth microdilution tests and antimicrobial interaction (synergy) studies using various combinations of cefoperazone and sulbactam were performed in an effort to determine the most appropriate in vitro dilution test system. The test results with cefoperazone and sulbactam were categorized as synergistic (complete or partial) for nearly 80% of the strains isolated from clinical trial patients. The results indicate that the cefoperazone-sulbactam fixed ratio (2:1) maximized the cefoperazone spectrum of activity and best approximated the parenteral formulation of the drug. The cefoperazone-sulbactam combination had a greater antimicrobial activity than did the other comparison beta-lactams, except for imipenem, tested against strains of the family Enterobacteriaceae. To be consistent with the National Committee for Clinical Laboratory Standards interpretive breakpoints for cefoperazone alone, the following MIC breakpoints should be applied to the combination (2:1 ratio): -<16/8 ,ug/ml, susceptible; 32/16 ,ug/ml, moderately susceptible; and -64/32 ,ug/ml, resistant.
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Beta-lactamase inhibitors, such as clavulanic acid, sulbactam, and YTR 830, have generally been used to expand the antimicrobial spectrum of beta-lactamase-labile beta-lactams (1-3, 5-9, 11, 16) . Aminopenicillins and ticarcillin have received the greatest attention by virtue of studies of amoxicillin-clavulanate (Augmentin), ticarcillin-clavulanate (Timentin), and ampicillin-sulbactam (Unasyn) (1) (2) (3) 8) .
Penicillins are usually hydrolyzed by the more frequently encountered bacterial beta-lactamases such as the staphylococcal penicillinases and gram-negative bacterial plasmid-mediated enzymes, i.e., TEM, SHV-1, and OXA (15) . Therefore, a significant spectrum enhancement could be achieved by combining penicillins with beta-lactamase inhibitors. The increased spectrum should also include remarkable activity against the Bacteroidesfragilis group and some other penicillin-resistant anaerobic bacteria (1, 3, 9) . The in vitro recognition of these favorable combinations has focused on the testing of both drugs in dilution and disk diffusion systems. Combinations administered as oral agents have been tested in vitro in fixed ratios, attempting to simulate in vivo pharmacokinetic conditions (13, 15) . In contrast, ticarcillin-clavulanic acid dilution tests use a single concentration of clavulanic acid (2.0 ,ug/ml) added to serial dilutions of ticarcillin. The kinetics of the drug at this concentration approximates the in vivo kinetics of the 100-or 200-mg intravenous inhibitor dose, and it is used in an attempt to recognize in vitro the favorable effects of the clavulanate (8, 13, 14) .
Cefoperazone, a widely used broad-spectrum cephalosporin, possesses acceptable beta-lactamase stability, especially against gram-positive and chromosome-mediated gramnegative enzymes (4) . However, some more frequently isolated beta-lactamases found in members of the family Eniterobacteriaceae can efficiently destroy cefoperazone (5, 10, 12) . Also, the cephalosporinases produced by the B.
* Corresponding author. firagilis group hydrolyze this newer cephalosporin (1, 3, 5, 6) .
Sulbactam combined with cefoperazone prevents its destruction by some clinically prevalent beta-lactamases, especially those produced by Esciherichia coli and the anaerobes. However, because of the very wide spectrum of activity of cefoperazone, the increased benefit due to the sulbactam appears small (,<5%) when routinely isolated clinical strains are tested (9, 11) . Therefore, in this investigation we concentrated our in vitro testing on those strains most often found to be resistant to cefoperazone and other newer cephalosporins. In addition, drug interaction studies with a fixed ratio and with single inhibitor concentrations were evaluated. The data were analyzed to determine the optimal method for testing the cefoperazone-sulbactam combination, correlating dilution test results to the parenteral formulation and pharmacokinetic properties of the drug.
( Antimicrobial susceptibility testing methods. MICs were determined by the broth microdilution method described in detail in previous reports (9) (10) (11) and by the National Committee for Clinical Laboratory Standards (13, 14) . The inoculum contained ca. 5 x 105 CFU/ml. Mueller-Hinton broth was supplemented with 2 to 3% lysed horse blood or other appropriate reagents (14) 4 .0 ptg/ml were added to increasing twofold dilutions of cefoperazone (range, 0.015 to 512 ptg/ml), and the two drugs were also combined in a ratio of 2 parts cefoperazone to 1 part sulbactam.
For the checkerboard drug interaction (synergy) technique, broth microdilution trays were prepared in which cefoperazone was combined with sulbactam. Methods and interaction definitions described previously and divalent cation-supplemented Mueller-Hinton broth or WilkinsChalgren broth were used (10) . Each test strain was inoculated into the plastic trays at a final density of 5 x 105 CFU/ml (106 CFU/ml for anaerobes) and then incubated overnight (for aerobes) or for 48 h (for anaerobes), the MICs were read, and isobolograms were plotted. A total of 333 drug synergy studies were performed. Synergy was considered a questionable significance if either drug was highly active (MIC, 'z1 ,ug/ml) against a strain when tested singly.
RESULTS
The results of testing 948 organisms against cefoperazonesulbactam combinations and three comparison drugs are shown in Table 1 Table 1 (data not shown). The members of the Enterobacteriaceae, S. aureus, Streptococcus spp., and enterococci were all susceptible to imipenem, but for P. aeruginosa and other Pseudomonas spp., imipenem resistance rates were 3 and 15%, respectively.
The in vitro antimicrobial spectrum of cefoperazone with and without sulbactam and those of four other drugs are shown in Table 2 . Cefoperazone-sulbactam inhibited 87% of the highly resistant members of the Enterobacteriaceae at the susceptible breakpoint concentration for cefoperazone (<16 1tg/ml) and 91% at the moderately susceptible concentration of c32 ,xg/ml. This spectrum was equal or superior to those of all other beta-lactams tested except imipenem. Cefoperazone-sulbactam was comparable or slightly superior to other comparison drugs against the Pseudomonas spp. and Acinetobacter spp. The coverage of gram-negative anaerobes by cefoperazone was improved from 65 to >99% by adding sulbactam in a 2:1 ratio. The proportions of anaerobes for which cefoperazone MICs were s32 Ftg/ml in combination with 2.0 and 4.0 tg of sulbactam per ml were 95 and 97%, respectively.
The aerobic strains were further analyzed for the incidence of at least fourfold reductions in cefoperazone MICs brought about by the addition of sulbactam. A fixed inhibitor concentration of 2 or 4 ,ug/ml was more active. A total of 173 strains showed a significant reduction of the cefoperazone MIC (fourfold lower) associated with any concentration or ratio of sulbactam. Nearly all of these isolates were already highly susceptible to cefoperazone alone (MIC, s1 ,ug/ml). The log2 dilution change in the aerobic-organism cefoperazone MICs with 4 ,ug of sulbactam per ml was -3.4. The cefoperazone dilution change at a 2:1 ratio was -2.1. Statistics for the gram-negative anaerobic bacteria were similar, with a mean -2.3 log2 dilution change in the cefoperazone MIC at the 2:1 ratio. The value for the fixed 4 ,ig/ml sulbactam concentration test was -2.5 dilutions.
Synergy testing was performed on 333 additional strains isolated from 242 patients participating in the cefoperazone- (1, 3, 5, 7, 9, 11, 16) . Furthermore, previous investigators have concluded that when routine fresh clinical isolates are tested, the addition of sulbactam at concentrations greater than 2.0 or 4.0 fig/ml rarely enhances the spectrum of cefoperazone (9, 11) . This observation was VOL. 25, 1987 on August 27, 2017 by guest http://jcm.asm.org/ Downloaded from In this study, we evaluated the in vitro activity of cefoperazone-sulbactam at a ratio of 2:1 against a population of organisms with unusually high cephalosporin resistance. cephalosporinase-producing strains of C. jfieundii, E. aerogenies, and E. cloa(ae to the spectrum of cefoperazone. On the other hand, little influence on the activity of cefoperazone was found with a 2:1 ratio in tests with Serrauia inarcescens isolates. This observation may be related to the high affinity of cefoperazone for the S. inarcescens betalactamase (12) . The greatest benefit of this combination, however. seemed to be achieved against the more clinically prevalent plasmid-mediated beta-lactamases (15) and favorable interactions were apparent with al tested sulbactam concentrations. The 2:1 ratio better simulates drug formulations and pharmacokinetics and allows recognition of the expanded spectrum of the combination against members of the Enterobacteria(ceae and some nonenteric gram-negative organisms resistant to other newer beta-lactams ( Table 1) .
As observed in earlier studies, cefoperazone MICs in the susceptible range (-16 ig/ml) were synergistically reduced by the presence of sulbactam (9, 11) . This was especially relevant for beta-lactamase-producing H. influenzae (16) 1, 3, 5) . Therefore, the fixed ratio of inhibitor and cefoperazone should have greater antimicrobial effects in the clinical setting and in diagnostic tests than the 2 ptg/ml single concentration advocated for ticarcillin-clavulanic acid (8, 13, 14) .
In conclusion, we recommend that the cefoperazonesulbactam antimicrobial combination be tested in vitro at a 2:1 ratio by standardized dilution methods (13, 14) . Consideration should be given to reassessing the validity of proposed 75/15 ,ug cefoperazone-sulbactam disk tests (15) . A higher sulbactam disk content, with a ratio closer to 2:1, may be required to recognize the cefoperazone-resistant strains that could respond (MICs, <16 ,ug/ml) in dilution tests with a 2:1 ratio (Barry et al., in press ). Results of in vitro dilution testing of cefoperazone-sulbactam (2:1 ratio) indicate that it has the widest spectrum of antimicrobial activity when compared directly with other newer cephalosporins, penicillins, aminoglycosides, and clavulanic acid combinations (12) . Only imipenem inhibited more bacterial strains.
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